Free Trial

Zurcher Kantonalbank Zurich Cantonalbank Buys 5,031 Shares of Insulet Co. (NASDAQ:PODD)

Insulet logo with Medical background

Zurcher Kantonalbank Zurich Cantonalbank increased its position in Insulet Co. (NASDAQ:PODD - Free Report) by 15.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,319 shares of the medical instruments supplier's stock after purchasing an additional 5,031 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.05% of Insulet worth $8,686,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PODD. Marshall Wace LLP purchased a new position in shares of Insulet in the second quarter worth $99,978,000. Baillie Gifford & Co. lifted its stake in Insulet by 30.8% during the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier's stock valued at $380,607,000 after acquiring an additional 443,783 shares during the period. Mizuho Securities USA LLC boosted its holdings in shares of Insulet by 5,928.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier's stock valued at $75,835,000 after acquiring an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after acquiring an additional 193,839 shares during the period. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock valued at $175,697,000 after purchasing an additional 163,388 shares during the last quarter.

Insulet Price Performance

Insulet stock traded down $0.29 during mid-day trading on Monday, hitting $266.49. The stock had a trading volume of 609,741 shares, compared to its average volume of 769,367. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm's 50 day moving average is $244.40 and its 200 day moving average is $214.37. The firm has a market capitalization of $18.69 billion, a P/E ratio of 45.68, a P/E/G ratio of 4.08 and a beta of 1.22. Insulet Co. has a one year low of $160.19 and a one year high of $279.40.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PODD shares. Canaccord Genuity Group raised their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Raymond James lifted their price objective on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. BTIG Research increased their target price on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a report on Friday, November 8th. Piper Sandler raised their target price on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. Finally, Barclays upped their price target on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $253.27.

Get Our Latest Stock Analysis on Insulet

Insulet Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Read More

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

→ Did You See Trump’s Bombshell Exec. Order 001? (From Banyan Hill Publishing) (Ad)

Should you invest $1,000 in Insulet right now?

Before you consider Insulet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.

While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines